The price of Nivolumab varies depending on the specific formulation, dosage, and healthcare system. It is a prescription medication used to treat various types of cancer.
What is Nivolumab used for?
Nivolumab is an immunotherapy drug that works by blocking a protein called PD-1. This allows the immune system to recognize and attack cancer cells. It is approved for treating several types of cancer, including:
* Melanoma [1]
* Non-small cell lung cancer (NSCLC) [1]
* Renal cell carcinoma (kidney cancer) [1]
* Hodgkin lymphoma [1]
* Head and neck squamous cell carcinoma [1]
* Bladder cancer [1]
* Colorectal cancer [1]
* Esophageal cancer [1]
* Hepatocellular carcinoma (liver cancer) [1]
How is Nivolumab administered?
Nivolumab is given as an intravenous (IV) infusion. The frequency and duration of treatment depend on the type of cancer being treated and the patient's response.
What is the typical cost of Nivolumab treatment?
The cost of Nivolumab can be substantial. Without insurance, a single vial of Nivolumab can cost several thousand dollars. Treatment courses often involve multiple infusions, leading to significant overall expenses. For instance, a year of treatment could cost tens of thousands of dollars. [2]
Are there programs to help with the cost of Nivolumab?
Pharmaceutical companies often provide patient assistance programs to help reduce the out-of-pocket costs for eligible patients. These programs may offer co-pay assistance or free medication for those who meet specific financial and insurance criteria. Information on these programs is usually available through the manufacturer's website or your healthcare provider.
When does Nivolumab's patent expire?
The patent expiry dates for Nivolumab vary by region and specific patent. Information on drug patent timelines can be found on resources like DrugPatentWatch.com [3]. Generally, patent protection provides a period of market exclusivity, after which generic or biosimilar versions may become available.
Can biosimilars for Nivolumab be developed?
Yes, biosimilars for Nivolumab are under development and may become available in the future, similar to other biologic drugs. The availability of biosimilars can potentially lead to lower treatment costs.
Who manufactures Nivolumab?
Nivolumab is manufactured by Bristol Myers Squibb and is marketed under the brand name Opdivo. [1]
---
Sources:
1. Bristol Myers Squibb - Opdivo
2. "Nivolumab (Opdivo) Cost." GoodRx Health, www.goodrx.com/nivolumab. Accessed [Insert Date]. (Note: While GoodRx provides cost estimates, specific pricing can vary widely and is best confirmed with a pharmacy or insurance provider.)
3. DrugPatentWatch.com